

Age-Standardized Expected Years of Life Lost: Quantification of Cancer Severity

Yueh Wang, MSc^{1,2}, RuRu Chun-Ju Chiang, PhD^{1,2}, Wen-Chung Lee, MD, PhD^{1,2}, Ying-Wei Wang, MD, PhD³

¹ Taiwan Cancer Registry, Taipei, Taiwan

² Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

³ Cancer Control and Prevention Division, Health Promotion Administration, Ministry of Health and Welfare, Taipei, Taiwan

BACKGROUND

The critical implications of the expected years of life lost (EYLL) index of cancer for health policy assessments have been largely overlooked. In this study, we advocate to standardize life lost indices, named age-standardized EYLL.

METHODS

We calculated the unstandardized EYLL (UEYLL) and the age-standardized EYLL (AEYLL) to facilitate comparisons among 20 major cancer types including cancers of oral cavity, nasopharynx, esophagus, stomach, colon, rectum, liver, pancreas, bronchus and lung, female breast, cervix uteri, corpus uteri, ovary, prostate, kidney, bladder, brain, thyroid, leukemia, and non-Hodgkin lymphoma from the Taiwan Cancer Registry (TCR) database. The International Cancer Survival Standard was used for calculating AEYLL.

RESULTS

A total of 797,314 patients aged more than 15 years between 2006 and 2015 were collected from the TCR database. The unstandardized EYLLs of three leading cancers for both genders were brain (22.5 years), esophagus (19.0 years), and pancreas (15.2 years). However, the age-standardized EYLLs of three leading cancers for both genders were pancreas (16.6 years), brain (15.7 years) and esophagus (14.6 years).

Table 1 Unstandardized EYLLs and age-standardized EYLLs of 20 cancers in men and women combined in Taiwan (standard error in parenthesis)

| Cancer type | Number of patients | Mean age at diagnosis | Unstandardized | | Age-standardized | |
|-----------------------------------|--------------------|-----------------------|----------------|------|------------------|------|
| | | | EYLL (SE) | Rank | EYLL (SE) | Rank |
| Pancreas | 17,994 | 67.6 | 15.2 (0.2) | 3 | 16.6 (0.2) | 1 |
| Brain | 6929 | 49.4 | 22.5 (1.5) | 1 | 15.7 (0.3) | 2 |
| Esophagus | 22,244 | 58.9 | 19.0 (0.4) | 2 | 14.6 (0.1) | 3 |
| Bronchus and lung | 109,075 | 68.0 | 13.0 (0.2) | 7 | 14.0 (0.1) | 4 |
| Liver | 112,904 | 64.5 | 14.7 (0.1) | 4 | 14.0 (0.1) | 5 |
| Leukemia | 18,120 | 57.4 | 11.9 (0.7) | 8 | 11.0 (0.3) | 6 |
| Stomach | 37,994 | 68.2 | 9.6 (0.3) | 10 | 10.6 (0.2) | 7 |
| Ovary | 12,308 | 52.0 | 13.7 (1.3) | 6 | 10.5 (0.5) | 8 |
| Oral cavity | 62,406 | 55.0 | 14.0 (0.3) | 5 | 9.8 (0.2) | 9 |
| Nasopharynx | 15,699 | 51.0 | 10.5 (0.9) | 9 | 8.0 (0.3) | 10 |
| Non-Hodgkin | 17,615 | 61.9 | 8.7 (0.7) | 11 | 7.7 (0.3) | 11 |
| Kidney | 10,812 | 61.2 | 6.9 (0.8) | 12 | 7.1 (0.6) | 12 |
| Colon | 79,349 | 66.6 | 6.3 (0.2) | 14 | 6.5 (0.1) | 13 |
| Rectum | 53,339 | 64.7 | 6.7 (0.3) | 13 | 6.3 (0.2) | 14 |
| Bladder | 20,920 | 69.6 | 5.3 (0.3) | 18 | 5.6 (0.3) | 15 |
| Cervix uteri | 16,665 | 57.4 | 5.9 (0.3) | 16 | 5.5 (0.2) | 16 |
| Corpus uteri | 17,336 | 54.3 | 5.4 (0.9) | 17 | 5.1 (0.4) | 17 |
| Female breast | 96,204 | 53.9 | 6.0 (0.5) | 15 | 4.3 (0.2) | 18 |
| Prostate | 43,320 | 73.2 | 2.8 (0.2) | 19 | 3.4 (0.5) | 19 |
| Thyroid | 26,081 | 48.4 | 2.1 (1.5) | 20 | 3.0 (0.8) | 20 |
| All cancers irrespective of types | 903,935 | 62.3 | 9.8 (0.1) | - | 8.9 (0.1) | - |

Table 2 Unstandardized EYLLs and age-standardized EYLLs of 16 cancers in men in Taiwan (standard error in parenthesis)

| Cancer type | Number of patients | Mean age at diagnosis | Unstandardized | | Age-standardized | |
|-----------------------------------|--------------------|-----------------------|----------------|------|------------------|------|
| | | | EYLL (SE) | Rank | EYLL (SE) | Rank |
| Pancreas | 10,224 | 66.7 | 15.2 (0.2) | 3 | 15.6 (0.2) | 1 |
| Esophagus | 20,745 | 58.4 | 19.3 (0.3) | 2 | 14.6 (0.1) | 2 |
| Brain | 3,923 | 49.5 | 20.0 (1.8) | 1 | 14.5 (0.3) | 3 |
| Bronchus and lung | 67,687 | 69.0 | 12.2 (0.2) | 6 | 13.8 (0.1) | 4 |
| Liver | 78,676 | 62.6 | 15.2 (0.1) | 4 | 13.4 (0.1) | 5 |
| Stomach | 23,977 | 69.0 | 9.2 (0.3) | 9 | 10.5 (0.3) | 6 |
| Leukemia | 10,695 | 58.3 | 11.1 (0.8) | 7 | 10.1 (0.4) | 7 |
| Oral cavity | 56,946 | 54.5 | 14.6 (0.3) | 5 | 10.0 (0.2) | 8 |
| Nasopharynx | 11,882 | 51.1 | 10.2 (0.8) | 8 | 8.0 (0.4) | 9 |
| Non-Hodgkin | 9,669 | 62.3 | 8.6 (0.9) | 10 | 7.5 (0.4) | 10 |
| Rectum | 32,286 | 64.8 | 6.6 (0.3) | 11 | 6.1 (0.2) | 11 |
| Kidney | 7,136 | 60.8 | 5.7 (0.7) | 13 | 6.1 (0.6) | 12 |
| Colon | 43,822 | 66.8 | 6.1 (0.3) | 12 | 6.0 (0.2) | 13 |
| Bladder | 14,869 | 69.5 | 4.3 (0.4) | 14 | 4.6 (0.3) | 14 |
| Thyroid | 6,188 | 49.9 | 4.1 (2.7) | 15 | 4.1 (0.8) | 15 |
| Prostate | 43,320 | 73.2 | 2.8 (0.2) | 16 | 3.4 (0.5) | 16 |
| All cancers irrespective of types | 502,842 | 63.7 | 10.6 (0.1) | - | 9.7 (0.1) | - |

Table 3 Unstandardized EYLLs and age-standardized EYLLs of 19 cancers in women in Taiwan (standard error in parenthesis)

| Cancer type | Number of patients | Mean age at diagnosis | Unstandardized | | Age-standardized | |
|-----------------------------------|--------------------|-----------------------|----------------|------|------------------|------|
| | | | EYLL (SE) | Rank | EYLL (SE) | Rank |
| Pancreas | 7,770 | 68.7 | 15.8 (0.4) | 2 | 18.0 (0.4) | 1 |
| Brain | 3,006 | 49.1 | 26.0 (2.1) | 1 | 17.1 (0.5) | 2 |
| Liver | 34,228 | 68.8 | 13.5 (0.2) | 6 | 15.1 (0.3) | 3 |
| Esophagus | 14,999 | 66.0 | 15.0 (1.0) | 3 | 15.0 (0.4) | 4 |
| Bronchus and lung | 41,388 | 66.2 | 14.3 (0.3) | 4 | 14.3 (0.2) | 5 |
| Leukemia | 7,425 | 56.1 | 13.5 (1.3) | 7 | 12.0 (0.5) | 6 |
| Stomach | 14,017 | 66.8 | 10.1 (0.4) | 10 | 10.8 (0.3) | 7 |
| Ovary | 12,308 | 52.0 | 13.7 (1.3) | 5 | 10.5 (0.5) | 8 |
| Kidney | 3,676 | 61.8 | 10.6 (1.6) | 9 | 9.2 (1.0) | 9 |
| Nasopharynx | 3,817 | 50.7 | 11.5 (2.5) | 8 | 8.6 (0.8) | 10 |
| Bladder | 6,051 | 70.0 | 7.7 (0.6) | 13 | 8.5 (0.6) | 11 |
| Non-Hodgkin | 7,946 | 61.5 | 8.6 (0.9) | 12 | 7.8 (0.6) | 12 |
| Oral cavity | 54,600 | 60.4 | 9.2 (1.2) | 11 | 7.7 (0.5) | 13 |
| Colon | 35,527 | 66.4 | 6.2 (0.3) | 15 | 7.0 (0.2) | 14 |
| Rectum | 21,053 | 64.6 | 7.0 (0.4) | 14 | 6.9 (0.4) | 15 |
| Cervix uteri | 16,665 | 57.4 | 5.9 (0.3) | 17 | 5.5 (0.2) | 16 |
| Corpus uteri | 17,336 | 54.3 | 5.4 (0.9) | 18 | 5.1 (0.4) | 17 |
| Female breast | 96,204 | 53.9 | 6.0 (0.5) | 16 | 4.3 (0.2) | 18 |
| Thyroid | 19,893 | 47.9 | 1.5 (1.2) | 19 | 3.6 (1.1) | 19 |
| All cancers irrespective of types | 401,093 | 60.4 | 8.6 (0.1) | - | 8.0 (0.1) | - |




Fig. 1 Unstandardized expected years of life lost (UEYLL) and age-standardized EYLL (AEYLL) associated with 20 cancers in men and women combined (a), 16 cancers in men (b), and 19 cancers in women (c).




Fig. 2 Scatterplots of mean ages at diagnoses and the unstandardized expected years of life lost (EYLL) associated with 20 cancers in men and women combined (a), 16 cancers in men (b), and 19 cancers in women (c), as well as the age-standardized EYLL associated with 20 cancers in men and women combined (d), 16 cancers in men (e), and 19 cancers in women (f).

Among 16 cancers in the men and 19 cancers in the women, pancreatic cancer was the most severe cancer in Taiwanese population, with the greatest age-standardized EYLL for men (15.6 years) and women (18.0 years). Negative correlations of moderate magnitudes were observed between the unstandardized EYLLs and the mean corresponding patient ages at the time of diagnosis among 20 cancers for both genders (correlation coefficient = -0.20). This indicated that a larger unstandardized EYLL for a cancer type may have been due to a younger mean age at diagnosis rather than greater severity. After adjusting the confounding effect of age, the age-standardized EYLL properly reflected the severity of the corresponding cancer type (correlation coefficient = 0.06).

CONCLUSION

The unstandardized EYLL represents an overall assessment of disease burden, whereas the age-standardized EYLL is a suitable measure of disease severity. We suggest that both measures be incorporated into routine annual reports of cancer statistics alongside the usual incidence and mortality rates and their age-standardized counterparts.

*This research has accepted in April and published online in May 2019 by BMC Public Health.

FUNDING

This work is supported by grants from the Health Promotion Administration (HPA), the Ministry of Health and Welfare in Taiwan (A1061011 & A1071122; the tobacco control and health care funds).

